YHLO

2022-02-10

Summary:





On February 10th, 2022, YHLO produced COVID-19 Rapid Antigen Test Kit was authorized by Japanese PMDA (Pharmaceuticals and Medical Devices Agency), which is supplied to YHLO’s Japanese marketing authorization holder, MBL (MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.). With the Japanese PMDA certificate, the product will be available for sale in Japan, which can be used for professional use and self-testing.

Previous: YHLO And C-Mer Donated 300,000 COVID-19 Antigen Tests To Hong Kong

Next: YHLO COVID-19 Rapid Ag Test Kits(self-test) Approved by BfArM

Home

About YHLO

Products

Services

News

Company Profile Milestone Corporate Values

About YHLO

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

More +

Clinical Solution CLIA ELISA LIA ESR COVID-19

Products

Based on the technology platforms of CLIA, ELISA, LIA and immunofluorescence, YHLO is specialized in diagnosis of autoimmunity, reproductive health, diabetes, infectious diseases etc.

More +